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1142-183 Association of Prehypertension by Joint National 
Committee 7 Criteria With Left Ventricular Structure and 
Function: The Strong Heart Study
Marilyn B. Lawrence Wright, Richard B. Devereux, Mary J. Roman, Marcello Chinali, Lyle 
G. Best, James Galloway, Richard R. Fabsitz, Elisa T. Lee, Ying Zhang, Barbara V. 
Howard, Weill Medical College of Cornell University, New York, NY
Background: Hypertension (HTN) and left ventricular (LV) structure and function predict
cardiovascular events. The JNC 7 prehypertension (preHTN) category lowers the blood
pressure (BP) level at which cardiovascular risk for the general population is considered
significant. Methods: Using JNC 7 criteria to define BP groups, we compared clinical
features and LV structure and function in 776 normal BP (nlBP), 859 preHTN, 1,074
stage 1 HTN and 379 stage 2 HTN Strong Heart Study participants. Results: Partici-
pants were mostly female (63%), mean age 60 ± 8 years. Compared to the nlBP group,
preHTN and HTN participants were older, more obese, more likely to have diabetes and
less likely to smoke (all p < 0.01), with no difference in gender distribution, mean LDL or
HDL cholesterol. Plasma creatinine was higher with HTN and urine albumin/creatinine
ratio higher with preHTN and HTN (both p < 0.05). After adjusting for differences among
groups in age, diabetes, body mass index, smoking, study center and plasma creatinine,
LV mass and geometry were significantly different with preHTN and HTN compared to
nlBP. Compared to nlBP participants, LV systolic and diastolic function was significantly
different in HTN but not preHTN participants. (Table 1) Conclusion: PreHTN is associ-
ated with significant abnormalities of LV geometry and an increased prevalence of LV
hypertrophy. It is not associated with significant LV systolic or diastolic dysfunction. Fur-
ther research on clinical cardiovascular risk in preHTN is needed. 
1142-184 Contribution of Apolipoprotein A5 Gene Variants to Left 
Ventricle Hypertrophy in Hypertensive African-
American Men
Deborah Lyn, Rigobert Lapu-Bula, Cheryl Pack, Jason Nguyen, Jan Morgan, Elizabeth 
Ofili, Morehouse School of Medicine, Atlanta, GA
Background: Left ventricle mass (LVM) has been associated with metabolic measures
such as triglyceride levles in hypertensives (HTN). Variations in triglyceride levels have
been linked with polymorphisms in the apolipoprotein A5 (ApoA5) gene. It has not been
ascertained whether changes in cardiac structure are linked to APOA5 gene variants
related to hypertensive LV hypertrophy (LVH). Methods: The —1131T>C and 56C>G
(S19W) variants of the ApoA5 gene were determined in 92 normotensive and 123 HTN
African Americans without hyperlipedemia, diabetes or prior cardiac event. Echocardio-
grahic LVM was assessed to define LVH (>134/110 g/m2 men/women). Results: HTN
men bearing the —1131C and 56C alleles (C:C haplotype) had a significantly higher LVM
index compared to those with (T:C) haplotype. This association existed after multivariant
analysis when adjusted for body mass index. No significant differences in LVM were seen
in HTN women or normotensives related to these variants. Consistent with other studies,
the frequency of the 56G variant was linked to higher fasting triglyceride (p=0.05) and
lower HDL cholesterol (p=0.03) levels only in HTNs. Conclusion: These data suggest an
increased susceptibility to LVH in HTN men who carry the —1131C variant in the pro-
moter region. This study raises the possibility that apoA5 levels may play a role in lipid
transport in the development of cardiac hypertrophy.
LVM Index by Haplotypes in HTN 
Mean± SD g/m2 indexed to body surface area (n). Men p<0.01 Women p=0.84, T:C vs
C:C
1142-185 Cardiac Structural and Functional Responses to Salt 
Loading in Spontaneously Hypertensive Rats
Jwari Ahn, Jasmina Varagic, Dinko Susic, Michel Slama, Edward D. Frohlich, Ochsner 
Clinic Foundation, New Orleans, LA
Background: Increased dietary salt intake induces cardiac fibrosis in the spontaneously
hypertensive rat (SHR), yet little information details its effects on LV function. In addition,
young rats seem to be more susceptible to salt excess than older.
Methods: SHR at 8 or 20 weeks of age were given 8% salt diet; age-matched controls
received standard rat chow. Echocardiographic indices, arterial pressure and LV hydrox-
yproline concentration were measured at 16 and 52 weeks in the young and aged adult
SHR groups, respectively.
Results: In most SHR, given salt excess increased arterial pressure, LV mass and
hydroxyproline concentration associated with impaired LV relaxation manifested by pro-
longed isovolumic relaxation time, decreased early (E) and atrial filling (A) velocity ratio
(E/A) and slower propagation velocity of early filling (Vp). LV systolic function remained
normal. One-fourth of the young adult salt-loaded SHR developed cardiac failure associ-
ated with systolic and diastolic dysfunction with greater LV mass and fibrosis. These rats
had lower arterial pressure, decreased fractional shortening and restrictive pattern of
mitral flow. Shorter deceleration time of E wave and increased E/Vp ratio, an index of LV
filling pressure, indicated increased LV stiffness.
Conclusions: Increased sodium sensitivity in SHR not only is manifested by further eleva-
tion of blood pressure, but significant cardiac dysfunction, most likely related to ventricu-
lar fibrosis, also occurs, especially in the young.
1142-186 Elevated Levels of Circulating Tissue Inhibitor of 
Metalloproteinase-1 Correlate With Impaired Diastolic 
Relaxation in Hypertension: Implications for Diastolic 
Heart Failure
Muzahir H. Tayebjee, Sunil K. Nadar, Robert J. Macfadyen, Gregory YH Lip, City 
Hospital, Birmingham, United Kingdom
Background
Hypertension(HT), hypertensive heart disease and left ventricular (LV) hypertrophy are
integral to symptomatic diastolic heart failure. Tissue inhibitor of metalloproteinase 1
(TIMP-1) is linked to extracellular matrix fibrosis and is elevated in HBP. We explored the
link between circulating TIMP-1, matrix metalloproteinase 9 (MMP-9) and resting
echocardiographic LV filling.
Methods: Circulating MMP-9 and TIMP-1 levels were measured in citrated plasma by
ELISA in 52 patients with HT (38 male, age 57 + 11yrs) and 24 controls (15 male, mean
age 53+ 12years). Demography and standard resting echocardiographic indices of dias-
Table 1
Normotension Prehypertension Hypertension
SBP(mmHg) 109.0 ± 0.8 127.7± 0.4 150.2±0.9**
DBP (mmHg) 73.2±0.7 84.0±2.9* 89.6±0.8**
LVEDD (mm) 46.8±0.6 48.5±0.5* 49.8± 0.4*
LVM (g) 134.1±4.0 156.2±3.2* 178.9±5.9**
BNP (pg/ml) 22.0±2.2 21.8±2.3 30.7±3.2*
Table 1. LV Structure and Function in Study Participants grouped by BP Category
Variable NlBP
(N = 776)
PreHTN
(N = 859)
Stage 1 HTN
(N = 1074)
Stage 2 HTN
(N = 379)
LV end-diastolic diameter 
(cm)
4.89 ± 0.43 4.95 ± 
0.479 
5.03 ± 0.547 
β
5.12 ± 0.582 
β
Relative wall thickness 0.34 ± 
0.044
0.35 ± 
0.045*
0.35 ± 
0.049*
0.36 ± 
0.061_
LV Mass/height2.7 (g/m2.7) 37.5 ± 7.96 40.6 ± 8.84β 44.0 ± 11.06 
β
48.3 ± 13.32 
β
Eccentric LV Hypertrophy 
(%)
10.6 18.9 29.1 β 42.3 β
Concentric LV Hypertrophy 
(%)
1.0 2.1 3.2 6.1*
Ejection fraction (%) 64 ± 7.1 64 ± 7.7 62 ± 9.9 _ 61 ± 11.4 β
E/A ratio 0.92 ± 
0.291
0.86 ± 
0.249
0.82 ± 
0.348*
0.80 ± 0.369
Statistical significance versus nlBP: * = p < 0.05,  α = p < 0.01,  β = p < 0.001
T:C C:C T:G C:G
Male 112± 31 (39) 141± 44 (14) (0) (0)
Female 99± 27 (41) 101± 28 (17) 104± 30 (7) 72 (1)
Arterial Pressure and Echocardiographic Indices
ADULT
CONTROL
ADULT 
SALT
without CF
ADULT SALT
with CF
AGED
CONTROL
AGED
SALT
Arterial 
Pressure
(mmHg)
206 ± 9 243 ± 8* 164 ± 18*† 207 ± 6 242 ± 78*
LV Mass (g) 0.86 ± 0.04 1.12 ± 0.04* 1.39 ± 0.07*† 1.31± 0.03 1.53 ± 
0.06*
Left End 
Diastolic
Diameter (cm)
0.73 ± 0.02 0.75 ± 0.01 0.85 ± 0.02*† 0.84 ± 0.01 0.87± 0.02
Fractional
Shortening (%)
41 ± 1 44 ± 1 35 ± 1*† 41.2 ± 1 44.3± 1
E/A 2.56 ± 0.12 1.50 ± 0.12* 2.54 ± 0.20† 2.58 ± 0.21 2.18± 0.15
Deceleration 
Time
of E Wave (sec)
0.045 ± 
0.001
0.040 ± 
0.002*
0.036 ± 
0.002*
0.046 ± 
0.002
0.042 ± 
0.002
Vp (cm/s) 28.5 ± 0.76 25.1 ± 0.56* 24.9 ± 1.22* 24.7 ± 0.65 24.6 ± 0.63
E/Vp 0.028 ± 
0.001
0.031 ± 
0.001
0.039 ± 
0.002*†
0.032 ± 
0.001
0.034 ± 
0.001
LV 
Hydroxyproline
(mg/g)
4.57 ± 0.17 5.75 ± 0.12* 6.84 ± 0.57*† 4.85 ± 0.24 6.02 ± 
0.49*
*p<0.05 vs Respective Control, †p<0.05 vs Adult Salt without CF
